SERINA THERAPEUTICS INC. (SER) Fundamental Analysis & Valuation

NYSEARCA:SER • US81751A1088

1.57 USD
-0.1 (-5.99%)
At close: Mar 5, 2026
1.57 USD
0 (0%)
After Hours: 3/5/2026, 8:20:44 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SER fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

SER gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. SER scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. SER Profitability Analysis

1.1 Basic Checks

  • In the past year SER has reported negative net income.
  • SER had a negative operating cash flow in the past year.
  • SER had negative earnings in each of the past 5 years.
  • SER had a negative operating cash flow in each of the past 5 years.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -124.61%, SER is doing worse than 80.19% of the companies in the same industry.
  • SER has a Return On Equity of -618.26%. This is in the lower half of the industry: SER underperforms 77.12% of its industry peers.
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • SER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SER Health Analysis

2.1 Basic Checks

  • SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SER has more shares outstanding
  • SER has less shares outstanding than it did 5 years ago.
  • SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • SER has an Altman-Z score of -12.99. This is a bad value and indicates that SER is not financially healthy and even has some risk of bankruptcy.
  • SER has a Altman-Z score of -12.99. This is in the lower half of the industry: SER underperforms 77.31% of its industry peers.
  • There is no outstanding debt for SER. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.99
ROIC/WACCN/A
WACC8.23%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • SER has a Current Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SER (2.24) is worse than 74.04% of its industry peers.
  • SER has a Quick Ratio of 2.24. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.24, SER is doing worse than 71.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SER Growth Analysis

3.1 Past

  • SER shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.97%, which is quite impressive.
  • SER shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.56%.
  • The Revenue for SER have been decreasing by -49.65% on average. This is quite bad
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.12% on average over the next years.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-34.1%
EPS Next 2Y-9.74%
EPS Next 3Y2.15%
EPS Next 5Y3.12%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2033 5M 10M 15M 20M 25M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. SER Valuation Analysis

4.1 Price/Earnings Ratio

  • SER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.74%
EPS Next 3Y2.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SER Dividend Analysis

5.1 Amount

  • SER does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SER Fundamentals: All Metrics, Ratios and Statistics

SERINA THERAPEUTICS INC.

NYSEARCA:SER (3/5/2026, 8:20:44 PM)

After market: 1.57 0 (0%)

1.57

-0.1 (-5.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners4.35%
Inst Owner Change-7.82%
Ins Owners7.28%
Ins Owner Change0%
Market Cap16.74M
Revenue(TTM)56.00K
Net Income(TTM)-11.14M
Analysts80
Price Target13.26 (744.59%)
Short Float %1.63%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16%
Min EPS beat(2)-53.76%
Max EPS beat(2)21.75%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 298.86
P/FCF N/A
P/OCF N/A
P/B 9.29
P/tB 9.29
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.01
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.61%
ROE -618.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.24%
Cap/Sales 96.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -12.99
F-Score3
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.45%
EPS Next Y-34.1%
EPS Next 2Y-9.74%
EPS Next 3Y2.15%
EPS Next 5Y3.12%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%154.9%
Revenue Next Year134.46%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-143.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.59%
OCF growth 3YN/A
OCF growth 5YN/A

SERINA THERAPEUTICS INC. / SER FAQ

What is the fundamental rating for SER stock?

ChartMill assigns a fundamental rating of 2 / 10 to SER.


Can you provide the valuation status for SERINA THERAPEUTICS INC.?

ChartMill assigns a valuation rating of 0 / 10 to SERINA THERAPEUTICS INC. (SER). This can be considered as Overvalued.


How profitable is SERINA THERAPEUTICS INC. (SER) stock?

SERINA THERAPEUTICS INC. (SER) has a profitability rating of 0 / 10.


How financially healthy is SERINA THERAPEUTICS INC.?

The financial health rating of SERINA THERAPEUTICS INC. (SER) is 6 / 10.